Utility of circulating tumor DNA for predicting prognosis in the management of resectable pancreatic cancer

Abstract

Background: The measurement of circulating tumor DNA (ctDNA) has been studied in several malignancies, including metastatic pancreatic cancer, but less is known about its utility in monitoring treatment response and recurrence in resectable pancreatic cancer. Methods: We conducted a systematic review of the literature examining the association of ctDNA with overall survival (OS) and disease-free survival. Results: Five articles met our exclusion criteria. Baseline and/or postoperative ctDNA was found to be associated with decreased OS and recurrence-free survival. Discussion: ctDNA has the potential to be used as a prognostic biomarker and to guide therapy in resectable pancreatic cancer.

Keywords

Pancreatic cancer / circulating tumor DNA / prognosis / survival

References

[1] Centers for Disease Control and Prevention, An update on cancer deaths in the United States, 2021. Available from: https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm [Last accessed on 20 July 2022].

[2] American Cancer Society, Cancer facts & figures 2021. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html [Last accessed on 20 July 2022].

[3] McGuigan A,Turkington RC,Coleman HG.Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes.World J Gastroenterol2018;24:4846-61 PMCID:PMC6250924

[4] Moletta L,Valmasoni M,Ponzoni A.Surgery for recurrent pancreatic cancer: is it effective?.Cancers (Basel)2019;11:991 PMCID:PMC6679234

[5] Komo T,Kondo N.Prognostic impact of para-aortic lymph node micrometastasis in pancreatic ductal adenocarcinoma.Ann Surg Oncol2016;23:2019-27

[6] Niedergethmann M,Knob S.[Detection of micrometastases after curative resection for ductal adenocarcinoma of the pancreas].Zentralbl Chir2001;126:917-21

[7] Ferrone CR,Thayer SP,Fernandez-delCastillo C.Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.J Clin Oncol2006;24:2897-902 PMCID:PMC3817569

[8] Pavai S.The clinical significance of elevated levels of serum CA 19-9.Med J Malaysia2003;58:667-72

[9] Kim JE,Lee JK,Rhee JC.Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.J Gastroenterol Hepatol2004;19:182-6

[10] Ballehaninna UK.Serum CA 19-9 as a biomarker for pancreatic cancer-a comprehensive review.Indian J Surg Oncol2011;2:88-100 PMCID:PMC3244191

[11] Ballehaninna UK.The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.J Gastrointest Oncol2012;3:105-19 PMCID:PMC3397644

[12] Duffy MJ,Lamerz R.Tumor markers in pancreatic cancer: a European Group On Tumor Markers (EGTM) status report.Ann Oncol2010;21:441-7

[13] Mandel P.Nuclear acids in human blood plasma.C R Seances Soc Biol Fil1948;142:241-3

[14] Leon SA,Sklaroff DM.Free DNA in the serum of cancer patients and the effect of therapy.Cancer Res1977;37:646-50

[15] Elazezy M.Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management.Comput Struct Biotechnol J2018;16:370-8 PMCID:PMC6197739

[16] Gorgannezhad L,Islam MN,Shiddiky MJA.Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies.Lab Chip2018;18:1174-96

[17] Hindson BJ,Masquelier DA.High-throughput droplet digital PCR system for absolute quantitation of DNA copy number.Anal Chem2011;83:8604-10 PMCID:PMC3216358

[18] Myllykangas S.Targeted deep resequencing of the human cancer genome using next-generation technologies.Biotechnol Genet Eng Rev2010;27:135-58 PMCID:PMC4340661

[19] Bettegowda C,Leary RJ.Detection of circulating tumor DNA in early- and late-stage human malignancies.Sci Transl Med2014;6:224ra24 PMCID:PMC4017867

[20] Diehl F,Choti MA.Circulating mutant DNA to assess tumor dynamics.Nat Med2008;14:985-90 PMCID:PMC2820391

[21] Konishi F.CEA doubling time and CEA half-life in the prediction of recurrences after colorectal cancer surgery.Jpn J Clin Oncol2002;32:41-2

[22] Dawson SJ,Murtaza M.Analysis of circulating tumor DNA to monitor metastatic breast cancer.N Engl J Med2013;368:1199-209

[23] Diaz LA Jr,Wu J.The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.Nature2012;486:537-40 PMCID:PMC3436069

[24] Misale S,Hobor S.Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.Nature2012;486:532-6 PMCID:PMC3927413

[25] Siravegna G,Buscarino M.Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.Nat Med2015;21:795-801

[26] Kim YW,Song Y.Monitoring circulating tumor DNA by analyzing personalized cancer-specific rearrangements to detect recurrence in gastric cancer.Exp Mol Med2019;51:1-10 PMCID:PMC6802636

[27] Siravegna G.Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients.Mol Oncol2016;10:475-80 PMCID:PMC5528968

[28] Tie J,Wang Y.Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.Ann Oncol2015;26:1715-22 PMCID:PMC4511218

[29] Mohan S,Rothwell DG.Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer.Sci Rep2019;9:11610 PMCID:PMC6690979

[30] Sugimori M,Tsuchiya H.Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.Cancer Sci2020;111:266-78 PMCID:PMC6942439

[31] Kruger S,Ross C.Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.Ann Oncol2018;29:2348-55

[32] Lee B,Cohen J.Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.Ann Oncol2019;30:1472-8 PMCID:PMC6771221

[33] Pietrasz D,Garlan F.Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker.Clin Cancer Res2017;23:116-23

[34] Groot VP,Javed AA.Circulating tumor DNA as a clinical test in resected pancreatic cancer.Clin Cancer Res2019;25:4973-84 PMCID:PMC7403524

[35] Kim MK,Park B.Prognostic implications of multiplex detection of.KRAS64:726-34

[36] Däbritz J,Hänfler J.Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9.Pancreas2009;38:534-41

[37] Steinberg WM,Anderson KK.Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas.Gastroenterology1986;90:343-9

[38] Wong T,Threadgold J.Molecular diagnosis of early pancreatic ductal adenocarcinoma in high-risk patients.Pancreatology2001;1:486-509

[39] Wang ZY,Zhu H,Pan XR..KRAS9:1295 PMCID:PMC6896365

[40] Sausen M,Adleff V.Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients.Nat Commun2015;6:7686 PMCID:PMC4634573